Editor’s note

One silver lining of the COVID-19 infection is that policy decisions have been fast tracked

Policymakers will have to balance incentives for the pharma sector to scale up production with strict monitoring on environmental…

API manufacturers will have to up their quality game to compete with the new competitors The 2019-nCoV infection, which has…

Urgent regulatory reform is needed to spur more proactive policies for proposed bulk drug and API parks which will make the…

Outbreaks like 2019-nCoV underline the need for more R&D investment in infectious diseases

Will the sector get their shocks post-budget, via a revamped UCPMP, further pricing woes, etc?

The over-dependence on China and other countries imperils not just the health of the pharma industry in India, but also that of…

The industry will always find ways to slip through legal loopholes. Will regulators catch up in 2020?

Wide price deviation between countries offering cheaper medications indicates the complexity of drug pricing strategies across…

With headwinds in overseas markets, it is vital for pharma companies in India to grow their presence in the domestic market. But…